Skip to Main Content

Advertisement

Skip Nav Destination

Multiple Myeloma

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

Keywords:

Daratumumab Maintenance Improves PFS in Newly Diagnosed Myeloma

A two-year daratumumab maintenance regimen administered every eight weeks significantly reduced the risk of disease progression or death, compared with observation alone, in patients...

For Newly Diagnosed Myeloma, Are Four Drugs Better Than Three?

With a recent expansion in the availability of treatments for multiple myeloma (MM), several regimens have been shown to improve survival outcomes in patients...

Teclistamab Demonstrates Promising Efficacy, Safety in Relapsed/Refractory Multiple Myeloma

Treatment with a subcutaneous formulation of teclistamab, a novel bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 receptors, was well tolerated and associated...

Daratumumab-KRd Quadruplet Therapy, AHCT, and Consolidation Therapy Lead to High MRD Negativity in Newly Diagnosed Myeloma

A two-year daratumumab maintenance regimen administered every eight weeks significantly reduced the risk of disease progression or death, compared with observation alone, in patients...

Isatuximab Plus RVd Improves MRD Negativity Rates in Patients With Newly Diagnosed Multiple Myeloma

The addition of isatuximab to lenalidomide, bortezomib, and dexamethasone (RVd) improved rates of measurable residual disease (MRD) negativity better than RVd alone in patients...

Advertisement

  CURRENT ISSUE
  Mid-January 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X